Divi’s Laboratories shares surged to a fresh 52-week high after strong Q2 FY27 results and positive broker commentary. Net profit rose 64% year-on-year to ₹1,127 crore, while revenue grew 35% to ₹3,676 crore. Brokerages highlighted growth potential in custom synthesis and peptides.
Divi’s Laboratories shares surged to a fresh 52-week high after strong Q2 FY27 results and positive broker commentary. Net profit rose 64% year-on-year to ₹1,127 crore, while revenue grew 35% to ₹3,676 crore. Brokerages highlighted growth potential in custom synthesis and peptides.
<iframe src="https://hindustansphere.com/embed/cluster/fe0c56ebefa1fe10cb594389988118b492246f93" width="100%" height="320" style="border:0;max-width:680px" loading="lazy" title="Divi's Laboratories shares hit record high rising 84% YTD; buy, sell or hold after Q2 results 2026? Brokerages report"></iframe>
